Thera-SAbDab

OTLERTUZUMAB

>   Structural Summary
TherapeuticOtlertuzumab
TargetCD37
Heavy ChainEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
Formatdi-scFv+Fc
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental TechnologyADAPTIR Monospecific Platform
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedTrubion Pharmaceuticals, Aptevo Therapeutics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Peripheral T-cell lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]